Research Article

Multisite Kinetic Modeling of ^{13}C Metabolic MR Using $[1-^{13}\text{C}]$ Pyruvate

Pedro A. Gómez Damián,^{1,2,3} Jonathan I. Sperl,¹ Martin A. Janich,^{1,4,5} Oleksandr Khagai,^{1,5} Florian Wiesinger,¹ Steffen J. Glaser,⁵ Axel Haase,³ Markus Schwaiger,⁴ Rolf F. Schulte,¹ and Marion I. Menzel¹

¹GE Global Research, 85748 Garching bei München, Germany

²Medical Engineering, Tecnológico de Monterrey, 64849 Monterrey, NL, Mexico

³Medical Engineering, Technische Universität München, 85748 Garching bei München, Germany

⁴Nuclear Medicine, Technische Universität München, 81675 Munich, Germany

⁵Chemistry, Technische Universität München, 85748 Garching bei München, Germany

Correspondence should be addressed to Marion I. Menzel; menzel@ge.com

Received 30 August 2014; Revised 6 November 2014; Accepted 13 November 2014; Published 8 December 2014

Academic Editor: David Maintz

Copyright © 2014 Pedro A. Gómez Damián et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hyperpolarized ^{13}C imaging allows real-time *in vivo* measurements of metabolite levels. Quantification of metabolite conversion between $[1-^{13}\text{C}]$ pyruvate and downstream metabolites $[1-^{13}\text{C}]$ alanine, $[1-^{13}\text{C}]$ lactate, and $[^{13}\text{C}]$ bicarbonate can be achieved through kinetic modeling. Since pyruvate interacts dynamically and simultaneously with its downstream metabolites, the purpose of this work is the determination of parameter values through a multisite, dynamic model involving possible biochemical pathways present in MR spectroscopy. Kinetic modeling parameters were determined by fitting the multisite model to time-domain dynamic metabolite data. The results for different pyruvate doses were compared with those of different two-site models to evaluate the hypothesis that for identical data the uncertainty of a model and the signal-to-noise ratio determine the sensitivity in detecting small physiological differences in the target metabolism. In comparison to the two-site exchange models, the multisite model yielded metabolic conversion rates with smaller bias and smaller standard deviation, as demonstrated in simulations with different signal-to-noise ratio. Pyruvate dose effects observed previously were confirmed and quantified through metabolic conversion rate values. Parameter interdependency allowed an accurate quantification and can therefore be useful for monitoring metabolic activity in different tissues.

1. Introduction

While ^{13}C magnetic resonance spectroscopy (MRS) has been utilized for *in vivo* imaging and spectroscopy of metabolism [1] for a long time, only the development of dynamic nuclear polarization (DNP) helped to overcome the inherent sensitivity limit; as through hyperpolarization using DNP followed by rapid dissolution, the ^{13}C MR signal can be amplified by more than 10,000-fold [2].

One of the most common and viable agents for *in vivo* use is $[1-^{13}\text{C}]$ pyruvate (PYR) [3]. After intravenous injection, it is transported to the observed tissue or organ under

observation, where it is enzymatically metabolized to its downstream metabolites $[1-^{13}\text{C}]$ alanine (ALA) by alanine transaminase (ALT), $[1-^{13}\text{C}]$ lactate (LAC) by lactate dehydrogenase (LDH), and $[^{13}\text{C}]$ bicarbonate (BC) by pyruvate dehydrogenase (PDH) to varying extent, depending on tissue type and predominant metabolic activity. At the same time PYR is in chemical exchange with $[1-^{13}\text{C}]$ pyruvate-hydrate (PYRH). As part of gluconeogenesis, PYR may also be carboxylated to oxaloacetate [4].

In order to quantify the metabolic exchange between PYR and its downstream metabolites, MRS data acquired over a certain time period after injection first require assignment of

spectral peaks [5] in the spectral domain and second require quantification of these peaks over time. Several different methods have been used for this time-domain analysis, and among these the most simple and robust method is the determination of metabolite signal ratios. These ratios are usually obtained from the peak metabolite signals [6] or through integrating over time [5]. The latter approach has been employed in our previous study, conducted by Janich et al. [5], where hyperpolarized PYR spectra were quantified for different PYR doses and subsequently used to determine the dose effects on Wistar rats based on time integrated metabolite signal ratios.

Although the approach of obtaining relative metabolite signal ratios, LAC to PYR or ALA to PYR, is straightforward and robust, independently if obtained from peak signal or time integrals, the results suffer from an increasingly strong T_1 weighting of the integral, which skews the resulting ratios. Furthermore, although time-domain visualization and signal ratio determination is an effective tool for assessing the effect of different PYR doses, it provides no quantitative kinetic data of metabolic exchange.

In order to achieve this quantification, different methods for kinetic modeling of hyperpolarized ^{13}C MR data have been reported. Most approaches, derived from the modified Bloch equations, represent a two-site interaction between PYR and one specific downstream metabolite, for example, either LAC or ALA [7–14]. Modeling can be extended to include more sites (intra- and extracellular) or more metabolites [9, 12] (for a comprehensive comparison, see [15]). Even so, presumably for robustness, previous work focuses primarily on fitting data with just one downstream metabolite, keeping most parameters fixed, or even model free, based on signal ratios [5, 16, 17]. When PYR is injected and the corresponding metabolic reactions begin to take place, PYR is not metabolized exclusively into ALA (or LAC), but it changes dynamically into all of the aforementioned downstream metabolites [18]. There is furthermore some skepticism, if the implicit assumption of rate constant stability holds in all applications [17] and there are few analyses on model parameter dependence on SNR [19]. In particular, metabolic conversion in the heart predominantly follows the PDH path producing BC [6, 20]. We therefore hypothesize that the simultaneous consideration of various metabolic pathways is necessary to obtain an accurate evaluation of *in vivo* metabolic conversion rates. On this basis, we propose using a mathematical framework for multisite modeling (similar to [8, 21, 22]) by simultaneously fitting different possible ^{13}C metabolic pathways for PYR, which can typically be observed after injection of pyruvate labeled in the $[1-^{13}\text{C}]$ position.

Additionally, although our prior work [5] evaluates quantification of spectra and employed a semiquantitative method to investigate metabolic conversion under different PYR doses (based on metabolite to PYR ratios), it does not provide fully quantitative kinetic data. Therefore, in this subsequent work we employ the experimental data obtained in [5] and implement the proposed multisite, dynamic model to determine metabolic conversion and signal decay rates for full

quantification of the kinetics of metabolic conversion. Furthermore, the proposed model gives access to effective longitudinal relaxation times ($T_{1\text{eff}}$), both for PYR and for the downstream metabolites.

Using the identical biological data, the kinetic parameters estimated by the multisite model are then compared to the parameters obtained using the two-site models proposed both in [8] and in [23]. The estimated parameters of all models are also compared between the three different doses utilized in [5], that is, 20, 40, and 80 mM (corresponding to 0.1, 0.2, and 0.4 mmol/kg bodyweight) of PYR, in order to evaluate the capability of the model for the assessment of dose response. As identical data is used, the evaluation allows for direct assessment of kinetic model stability and quality. Ideally, a successful kinetic model would allow the reduction of data variability due to modeling to a minimum, allowing the visualization of biological variability (i.e., as a response to dose treatment, etc.). In addition, using simulated metabolic data based on exemplary conversion rates, we assessed the variability and stability of the kinetic models under the influence of noise. Here, the expectation towards a model is that both systematic bias and standard deviation of the resulting metabolic conversion rates should be as low as possible over a large range of signal-to-noise ratio (SNR).

2. Theory

In our previous study [5], MRS spectral data after injection of pyruvate was acquired and analyzed utilizing time-domain fitting with AMARES [24], resulting in a time course of metabolite levels. To quantify the metabolic conversion, this previous study employed integrated metabolite signal ratios. In the following paragraphs, we will compare this simple integrative approach to kinetic modeling using three different approaches, which are two-site exchange differential model, two-site exchange integral model, and multisite exchange integral model.

2.1. Two-Site Exchange Differential Model. Using a two-site exchange differential model (2SDM) allows computing metabolic exchange rates $k_{\text{pyr} \rightarrow x}$ and the respective metabolite's effective signal decay rates r_x by solving a system of linear equations given in differential form

$$\frac{dM_x(t)}{dt} = -r_x M_x(t) + k_{\text{pyr} \rightarrow x} M_{\text{pyr}}(t). \quad (1)$$

The effective metabolite signal decay rate r_x is dominated by T_1 relaxation, the respective backward metabolic exchange rate $k_{x \rightarrow \text{pyr}}$, and a flip angle (FA) term, which also depends on the repetition time (TR), accounting for the irreversible consumption of signal after successive excitations:

$$r_x = \frac{1}{T_x} + k_{x \rightarrow \text{pyr}} + f(\text{FA}) \quad (2)$$

with

$$f(\text{FA}) = \frac{1 - \cos(\text{FA})}{\text{TR}}. \quad (3)$$

Hence, r_x results in a single, inseparable term of signal decay. However, FA and TR are known from experimentation and

can be corrected for. In case the backward exchange rate $k_{x \rightarrow \text{pyr}}$ is assumed to be negligible, true T_1 relaxation times can be quantified; however, it remains unclear whether this assumption holds true in all physiological states of the animal.

2SDM does not assume a PYR input function and for that reason the first order differential equation (1) can be solved as a linear system. This approach is independent of the time course of PYR administration and is therefore straightforward to apply.

2.2. Two-Site Exchange Integral Model. Another approach in kinetic modeling, the two-site exchange integral model (2SIM), assumes a PYR input function that represents the PYR signal in time ($M_{\text{pyr}}(t)$). In Zierhut et al. [8] a series of piecewise defined exponential equations were presented:

$$M_{\text{pyr}}(t) = \begin{cases} \frac{I_{\text{pyr}}}{r_{\text{pyr}}} [1 - e^{-r_{\text{pyr}}(t-t_{\text{arrival}})}], & t_{\text{arrival}} \leq t < t_{\text{end}}, \\ M_{\text{pyr}}(t_{\text{end}}) e^{-r_{\text{pyr}}(t-t_{\text{end}})}, & t \geq t_{\text{end}}. \end{cases} \quad (4)$$

The first part of the equation takes into account PYR signal loss due to r_{pyr} and the injection of PYR with a constant rate I_{pyr} from the arrival time t_{arrival} until t_{end} . It nevertheless assumes that no conversion of PYR takes place during injection. The second part, for all time measurements later than t_{end} , is characterized only by the PYR signal loss. In a similar manner, an assumption on the initial PYR concentration can be made instead of an assumption on the input function, leading to the modeling of only the exponential decay, as shown in [25]. Explicit modeling of M_{pyr} allows for (1) to be solved yielding metabolite signals in time [8]:

$$M_x(t) = \begin{cases} \frac{k_{\text{pyr} \rightarrow x} I_{\text{pyr}}}{r_{\text{pyr}} - r_x} \left[\frac{1 - e^{-r_x(t-t_{\text{arrival}})}}{r_x} - \frac{1 - e^{-r_{\text{pyr}}(t-t_{\text{arrival}})}}{r_{\text{pyr}}} \right], & t_{\text{arrival}} \leq t < t_{\text{end}}, \\ \frac{M_{\text{pyr}}(t_{\text{end}}) * k_{\text{pyr} \rightarrow x}}{r_{\text{pyr}} - r_x} [e^{-r_x(t-t_{\text{end}})} - e^{-r_{\text{pyr}}(t-t_{\text{end}})}] + M_x(t_{\text{end}}) e^{-r_x(t-t_{\text{end}})}, & t \geq t_{\text{end}}. \end{cases} \quad (5)$$

Alongside the parameters characterizing the PYR input function, these equations contain the same parameters ($k_{\text{pyr} \rightarrow x}$ and r_x) that were solved for using 2SDM.

2SIM can be considered as a two-step approach. First, t_{arrival} , r_{pyr} , and I_{pyr} are determined by fitting (4) to the measured PYR signal. t_{end} is simply calculated by summing t_{arrival} and the known injection duration. These parameters are then utilized to fit (5) to the LAC and ALA signals. In [6], this model is also utilized to fit the BC signal. Finally the computed metabolic exchange rates $k_{\text{pyr} \rightarrow x}$, the decay rate r_{pyr} , and the flip angle correction (3) can be used to estimate apparent T_1 relaxation of PYR.

2.3. Multisite Exchange Integral Model. As described above, the metabolite signal decay rate r_x depends on T_1 relaxation, backward metabolic exchange rates $k_{x \rightarrow \text{pyr}}$, and signal loss from flip angle variations. On the other hand, the PYR signal decay rate r_{pyr} does not depend on backward metabolic exchange, but on forward metabolic exchange rates $k_{\text{pyr} \rightarrow x}$. This signifies that the rate of PYR decay is also proportional to the rate of PYR downstream conversion.

Hence, when passing from 2SIM to a multisite exchange integral model (MSIM), the PYR input function (4)—represented in its differential form—needs to include all of the metabolic exchange rates:

$$\frac{dM_{\text{pyr}}(t)}{dt} = \begin{cases} -r_{\text{pyr}} M_{\text{pyr}}(t) - \sum_x k_{\text{pyr} \rightarrow x} M_{\text{pyr}}(t) + I_{\text{pyr}}, & t_{\text{arrival}} \leq t < t_{\text{end}}, \\ -r_{\text{pyr}} M_{\text{pyr}}(t) - \sum_x k_{\text{pyr} \rightarrow x} M_{\text{pyr}}(t), & t \geq t_{\text{end}}. \end{cases} \quad (6)$$

Note that both the PYR signal decay rate r_{pyr} and the sum of all of the metabolic exchange rates $\sum_x k_{\text{pyr} \rightarrow x}$ are multiplied by the same term $M_{\text{pyr}}(t)$ and can therefore be grouped into a total PYR signal decay rate:

$$R_{\text{pyr}} = r_{\text{pyr}} + \sum_x k_{\text{pyr} \rightarrow x}. \quad (7)$$

By replacing (7) in (6), the integral form of the new PYR input function reads

$$M_{\text{pyr}}(t) = \begin{cases} \frac{I_{\text{pyr}}}{R_{\text{pyr}}} [1 - e^{-R_{\text{pyr}}(t-t_{\text{arrival}})}], & t_{\text{arrival}} \leq t < t_{\text{end}}, \\ M_{\text{pyr}}(t_{\text{end}}) e^{-R_{\text{pyr}}(t-t_{\text{end}})}, & t \geq t_{\text{end}}. \end{cases} \quad (8)$$

The representation of the total PYR relaxation rate R_{pyr} as the sum of the PYR relaxation rate and the metabolic conversion rates allows for a simultaneous fitting process, where the conversion rates are taken into account also in the PYR input function, creating dependent curves and a parameter interdependency. In addition, the estimation of T_1 values for PYR can be achieved directly using

$$\frac{1}{T_{1\text{pyr}}} = r_{\text{pyr}} - f(\text{FA}). \quad (9)$$

Utilizing the same R_{pyr} term for the metabolite signals, (5) becomes

$$M_x(t) = \begin{cases} \frac{k_{\text{pyr} \rightarrow x} I_{\text{pyr}}}{R_{\text{pyr}} - r_x} \left[\frac{1 - e^{-r_x(t-t_{\text{arrival}})}}{r_x} - \frac{1 - e^{-R_{\text{pyr}}(t-t_{\text{arrival}})}}{R_{\text{pyr}}} \right], & t_{\text{arrival}} \leq t < t_{\text{end}}, \\ \frac{M_{\text{pyr}}(t_{\text{end}}) * k_{\text{pyr} \rightarrow x}}{R_{\text{pyr}} - r_x} [e^{-r_x(t-t_{\text{end}})} - e^{-R_{\text{pyr}}(t-t_{\text{end}})}] + M_x(t_{\text{end}}) e^{-r_x(t-t_{\text{end}})}, & t \geq t_{\text{end}}. \end{cases} \quad (10)$$

As seen in (2), the backward exchange rates are inseparably confounded with T_1 in the respective signal decay rate r_x of each metabolite. A nonnegligible backward reaction thus leads to an overestimation of the true T_1 values for all of the downstream metabolites. For LAC, the overestimation might be considered negligible since the backward reaction was reported to have only a very small effect on kinetics [26], although earlier work indicates upregulated gluconeogenesis in liver-metabolism of tumor-bearing rats [27]. The assumption of negligible backward reactions might also not hold for ALA. There is no need to apply a backward exchange to BC; however, depending on pH, it is breathed out as $^{13}\text{CO}_2$ and this could lead to an apparent shortening in T_1 . This signifies that the T_1 values for ALA and BC obtained utilizing this model can only be considered bounds for the true value.

3. Methods

3.1. Experimental Data. The experimental data was obtained from healthy male Wistar rats through the acquisition of slice-selective FID signals in heart, liver, and kidney tissue. Three different hyperpolarized PYR concentrations (20, 40, and 80 mM, which correspond to an injected dose of 0.1, 0.2, and 0.4 mmol/kg bodyweight) were utilized to measure a total of 15 animals. Each dose was injected into five different animals twice, resulting in a total of 10 measurements for each dose. A flip angle of 5° was utilized and TR was triggered to animal breathing yielding an average value of ~ 1 s. SNR was calculated by dividing the maximum PYR signal by the average noise for all time steps. More experimental details can be directly found in [5].

Further exemplary data to evaluate modeling performance at presence of pathology were obtained from adult female Fischer 344 rats (Charles River, Sulzfeld, Germany) bearing subcutaneous mammary adenocarcinomas. The animals' anesthesia was maintained with 1–3% isoflurane in oxygen starting about 1 h before the first injection. During the experiment, the heart rate, temperature, and breathing signal were monitored using an animal monitoring system (SA Instruments, Stony Brook, NY, USA). All ^{13}C animal experiments were approved by the regional governmental commission for animal protection (Regierung von Oberbayern, Munich, Germany). Two injections were performed using an 80 mM concentration, allowing for direct comparison. For this set of experiments, a flip angle of 10° was utilized and TR was fixed to 1 s.

3.2. Data Processing. The experimental data $y_{m,i}$ with $m \in \{\text{lac}, \text{ala}, \text{pyr}, \text{bc}\}$ acquired at time steps t_i was fitted to MSIM in a constrained least-squares sense; that is,

$$\min_{\beta} f(\beta) \quad \text{s.t. } \text{lb} \leq \beta \leq \text{ub}, \quad (11)$$

with cost function

$$f(\beta) = \sum_m \sum_i (y_{m,i} - M_m(t_i, \beta))^2, \quad (12)$$

parameters $\beta = [r_{\text{lac}}, \dots, r_{\text{bc}}, k_{\text{pyr} \rightarrow \text{lac}}, \dots, k_{\text{pyr} \rightarrow \text{bc}}, I_{\text{pyr}}, t_{\text{end}}]$, and lower and upper bounds lb and ub, respectively. While

t_{arrival} was fixed to the time when the PYR signal reached 10% of its maximum peak value, t_{end} was set as a fitting parameter accounting for various injection times. On the contrary, the implementation in [8] kept t_{end} fixed while fitting for t_{arrival} . Even though the duration of the injection was known, fixing t_{arrival} in function of its peak value and calculating t_{end} as a parameter allowed for different delivery and perfusion times. Delivery, perfusion, and export are however not implicitly included in the model. To improve the convergence properties of the optimization, the gradient of the cost function was calculated analytically. The optimization was carried out using the MATLAB function *fmincon* (MathWorks, Natick, MA, USA) employing the *Trust Region Reflective Algorithm* and a function tolerance of $1E-10$. The utilized bound constraints were set to physically relevant limits: upper bounds of 0.1 s^{-1} for metabolic conversion rates $k_{\text{pyr} \rightarrow x}$, since they have been reported to be of a smaller order [8, 23], and of 0.005 s^{-1} for the decay rates r_x (equivalent to a 200 s inverse effective signal decay rate) and lower bounds establishing the positivity of all parameters. Note that the optimization always converged far away from the bounds and they were only implemented for numerical improvement. After optimization, T_1 values were estimated for all metabolites from the effective signal decay rate (see (2) and (9)). Initial conditions were fixed to expected normal parameters; however, randomizing the starting guess in between bounds and performing various iterations yielded comparable results.

Pyruvate-hydrate (PYRH), which is also present in spectroscopy, was not included in the minimization process. The reason for this is that conversion between PYR and PYRH is not enzymatic and we are interested in quantifying metabolic rates that lead to a better understanding of enzymatic activity. Additionally, since chemical exchange with PYRH is instantaneous and almost in equilibrium, including PYR would require adding three extra parameters to the minimization without providing additional information regarding metabolic activity. In fact, if PYRH were to be included, the immediate conversion of PYR to PYRH would lead to an overestimation of the apparent metabolic rate, which in turn would decrease all other parameters intrinsic in R_{pyr} leading to an overestimation of T_1 values for PYR.

The same reasoning holds for the exclusion of additional pools. Although the MSIM model can be further extended to include multiple pools [15, 22], including them only adds variables to the minimization with no direct benefit to the determination of enzymatic conversion rates.

4. Results

4.1. Convergence and Quality of Fit. Parameter fitting with MSIM was shown to converge to an optimal point for every set of experimental data. Figures 1(a)–1(c) show the fitted curves of all metabolites for all models. The residuals for every metabolite and every measurement in the time domain were analyzed (Figures 1(d)–1(f)), and the error of the fitted curves and computed parameters was determined based on the parameter covariance matrix [28]. This error was utilized to determine 95% confidence intervals on the fitted data (see Figures 1(a)–1(c)).

FIGURE 1: Example of metabolic data acquired for a 40 mM (0.2 mmol/kg) dose in kidney predominant tissue, fitted curves (solid lines) using (a) MSIM, (b) 2SIM, and (c) 2SDM and 95% confidence intervals (dotted lines). (d–f) Residuals of fit.

TABLE 1: Exemplary parameter estimates ($\pm$ standard error) obtained from three different kinetic modeling methods for a 40 mM (0.2 mmol/kg) dose of kidney predominant tissue.

Model	MSIM	2SIM	2SDM
$k_{\text{pyr} \rightarrow \text{lac}} [\text{s}^{-1}]$	$0.03194 \pm 9.71E-04$	$0.03202 \pm 7.75E-04$	$0.03448 \pm 1.15E-03$
$k_{\text{pyr} \rightarrow \text{ala}} [\text{s}^{-1}]$	$0.02507 \pm 1.07E-03$	$0.02518 \pm 4.97E-04$	$0.02832 \pm 1.02E-04$
$k_{\text{pyr} \rightarrow \text{bc}} [\text{s}^{-1}]$	$0.00379 \pm 1.51E-03$	$0.00381 \pm 2.67E-04$	$0.00392 \pm 4.48E-04$
$T_{1\text{lac}} [\text{s}]$	16.36 ± 0.620	16.28 ± 0.488	14.13 ± 0.629
$T_{1\text{ala}} [\text{s}]$	14.48 ± 0.752	14.38 ± 0.552	12.18 ± 0.578
$T_{1\text{bc}} [\text{s}]$	14.11 ± 4.78	14.11 ± 1.19	13.46 ± 2.051
$T_{1\text{pyr}} [\text{s}]$	16.67 ± 0.676	16.82 ± 0.845	N/A*

* According to (1), 2SDM only fits for $k_{\text{pyr} \rightarrow x}$ exchange rates and the corresponding T_1 values.

FIGURE 2: Metabolic conversion rates of LAC (left), ALA (center), and BC (right) obtained for heart, kidney, and liver predominant slices at 20, 40, and 80 mM concentrations (0.1, 0.2, and 0.4 mmol/kg doses) for 2SDM (top), 2SIM (center), and MSIM (bottom). Every box plot displays minima, 25th percentiles, medians, 75th percentiles, maxima, and outliers.

Note that for both MSIM and 2SIM the residuals have a distinct pattern. The pattern indicates that a linear injection rate does not fully model biological activity. In [9], the input function is modeled as a trapezoidal instead of a linear input, but the authors provide no residual analysis. On the other hand, assuming no input function by establishing a fixed initial PYR concentration [25] or solving the differential linear system may not fully account for the entire kinetic time course of the measured signals. In any case, this should be considered as a limitation for both models.

4.2. Model Comparison. For all of the experimental data, parameters were obtained utilizing the 2SDM, the 2SIM, and the MSIM. While a single implementation of MSIM brought

forth parameter values for all downstream metabolites, an independent implementation for LAC, ALA, and BC was necessary in the two-site models. Since all three models were applied on exactly the same experimental data, the comparison between them and to the results obtained for the integrated metabolite signal ratios obtained from Janich et al. [5] directly allows assessing model accuracy separated from biological variability and experiment related inaccuracies like low SNR levels. Results from one exemplary minimization are shown in Table 1; Table 2 displays mean estimated $T_{1\text{pyr}}$ values for all experiments and their respective SNR levels; and Figure 2 details the obtained metabolic conversion rates for all three models.

TABLE 2: $T_{1\text{PYR}}$ calculated for MSIM and 2SIM and corresponding SNR levels for all concentrations and slices (mean $\pm$ standard deviation).

	$T_{1\text{PYR}}$ (MSIM)	$T_{1\text{PYR}}$ (2SIM)	SNR
20 mMol			
Heart	8.93 ± 2.68	9.04 ± 2.82	15.52 ± 3.87
Liver	22.14 ± 12.26	24.25 ± 14.28	8.62 ± 2.03
Kidney	27.63 ± 12.11	61.61 ± 91.27	11.63 ± 1.87
40 mMol			
Heart	10.02 ± 2.81	10.17 ± 2.88	44.57 ± 15.56
Liver	20.70 ± 3.72	22.83 ± 8.44	20.14 ± 6.36
Kidney	21.11 ± 7.04	21.73 ± 9.20	27.58 ± 5.38
80 mMol			
Heart	10.85 ± 5.98	10.94 ± 6.11	84.65 ± 32.32
Liver	25.75 ± 7.90	25.88 ± 7.89	23.06 ± 14.60
Kidney	20.69 ± 10.38	20.00 ± 10.33	29.61 ± 12.95

Conversion rates and $T_{1\text{PYR}}$ values calculated with MSIM tended to be lower than those of 2SIM and these in turn are lower than 2SDM (see Tables 1 and 2). Although performance is very similar for all models, reduced data spread can be observed in PYR to LAC conversion in kidney predominant tissue (Figure 2). Since MSIM fits up to nine parameters simultaneously, estimated error from the parameter covariance matrix was usually higher for MSIM.

Additionally, for an exemplary dataset, a noise analysis of all three models was implemented by adding Gaussian noise to different extent. Parameters were first obtained from an exemplary minimization with MSIM and were then subsequently used for time curve simulation. Every model was then fit 1,000 times with different initial parameters to this simulated time curve to create a model specific ground truth. Finally, based once again on 1,000 iterations, the simulated dataset was corrupted with random Gaussian noise and minimized with each model. Figure 3 displays mean and standard deviation of $k_{\text{PYR} \rightarrow \text{LAC}}$ values up to a 10% noise level.

Figure 3 illustrates that although all models yield the same results in noise-free data, with increasing noise both bias and standard deviation of the two-site models 2SIM and 2SDM increase. As a consequence, the resulting metabolic conversion rates obtained from these two-site models increasingly suffer from systematic under- or overestimation. In contrast, the simulation demonstrates that the MSIM model remains bias-free, even with increased noise level, while exhibiting the smallest standard deviation compared to the two-site models.

From experimental results, it is clear that SNR increases with higher concentrations of injected PYR and that 20 mMol injections in liver and kidney predominant tissue had the lowest SNR (with corresponding noise levels of nearly 10%), whereas SNR in heart was generally higher but had a larger standard deviation (Table 2). According to noise simulations, it is precisely in low SNR regions that MSIM is expected to perform with lower deviations. Standard deviations for $T_{1\text{PYR}}$ values and reduced data spread in 20 mMol k_{PYR} quantification, especially in kidney predominant tissue, are indications that this holds.

FIGURE 3: Noise level analysis for exemplary simulated data. Error bars show mean $\pm$ standard deviation.

4.3. Pyruvate Dose Assessment. The effects of PYR dose on Wistar rats were examined through the injection of solutions with concentrations of 20, 40, and 80 mM (doses of 0.1, 0.2, and 0.4 mmol/kg) hyperpolarized PYR. Kinetic data was obtained for all downstream metabolites and visualized with the same box plots used in [5]. With this approach, a direct comparison between the results previously obtained and the results obtained with kinetic modeling could be made, using median values as a distance dimension between the results obtained by the different models, rather than as confirmatory values (see Figure 2). As in [5], all median values suggest saturation effects. A more detailed assessment of the PYR dose effects on metabolism and its biological interpretation can be found in [5].

4.4. Tumor Evaluation. In tumor cells, it is well known that conversion from PYR to LAC is elevated even in the presence of oxygen [29, 30]. Additionally, some tumors show changes in alanine transaminase activity, leading to suppression of conversion of PYR to ALA [31–34]. Both effects were quantified by comparing experimental data obtained from a healthy rat and a rat with mammary carcinoma and using MSIM to obtain conversion rate parameters (see Figure 4). It can be seen that, for the same dose, the $k_{\text{PYR} \rightarrow \text{LAC}}$ conversion rate was more than four times larger in tumor cells than healthy cells and the $k_{\text{PYR} \rightarrow \text{ALA}}$ rate was more than 18 times larger in healthy cells than tumor cells. Therefore, obtained conversion rates provide a quantitative metric of metabolic differences between healthy and tumor cells.

5. Discussion and Conclusion

Three different kinetic modeling methods were implemented and investigated for the quantification of time-dependent metabolite levels. The two-site exchange differential model (2SDM) and two-site exchange integral model (2SIM) assume a two-site interaction between pyruvate (PYR) and one specific metabolite. The proposed multisite exchange integral model (MSIM) takes into account various downstream metabolites in one system and allows fitting in a one-step process. That is, all of the parameters are generated in a single

FIGURE 4: Comparison of $k_{\text{pyr} \rightarrow \text{lac}}$ and $k_{\text{pyr} \rightarrow \text{ala}}$ conversion rates between a healthy rat (from an 80 mM dose in kidney predominant tissue) and a rat with mammary carcinoma.

minimization, avoiding the need for separate implementations for every specific metabolite and resulting in a robust, optimal convergence far from the imposed constraints.

The three models were compared by taking median values as a distance dimension and, using exemplary simulated data, performing a noise analysis. In this analysis, metabolic exchange rate values obtained with 2SDM and 2SIM showed a bias with increasing noise levels. On the other hand, MSIM showed almost no bias, maintaining the average computed value close to the ground truth even at high noise levels, with smaller standard deviations than 2SDM and 2SIM.

Using the experimental data of [5], all kinetic models were compared between different PYR concentrations to assess the effect of increased PYR doses on *in vivo* metabolism. Results obtained from all three kinetic models were very similar; however, MSIM yielded smaller data spread for metabolic conversion in low SNR experiments and more accurate effective T_1 values for PYR as downstream metabolite rates are taken into account during the optimization, while effective T_1 -estimation in 2SIM requires postprocessing corrections.

MSIM was then further utilized to evaluate model performance in disease. Obtained conversion rates from MSIM showed significant differences in healthy cells in comparison to tumor cells, where LAC conversion was elevated and ALA conversion, on the other hand, was suppressed.

Extending two-site models into a multisite model yields both biological and numerical insight. Biologically, it has been shown that calculated rates give proof of the saturation effects studied in [5] and can be used to quantify metabolic differences between normal and tumor cells. Numerically, a one-step fitting process with parameter interdependency

performs marginally better than other fitting methods, particularly in regions with low SNR. Further work with the MSIM model will focus on pixelwise metabolic mapping of cellular activity and its application to different metabolic systems.

Abbreviations

x :	Index of downstream metabolites: lactate, alanine, bicarbonate, and pyruvate-hydrate
$k_{\text{pyr} \rightarrow x}$:	Metabolic conversion rate from pyruvate to x
LDH:	Lactate dehydrogenase
ALT:	Alanine transaminase
PDH:	Pyruvate dehydrogenase
CA:	Carbonic anhydrase
2SDM:	Two-site differential model
2SIM:	Two-site integral model
MSIM:	Multisite integral model
$M_x(t)$:	Time dependent signal for metabolite x
$M_{\text{pyr}}(t)$:	Time dependent pyruvate signal
$f(\text{FA})$:	Flip angle function
t_{arrival} :	Time of pyruvate arrival
t_{end} :	Time at which pyruvate is no longer injected
I_{pyr} :	Pyruvate injection rate
r_x :	Metabolite signal decay
r_{pyr} :	Pyruvate signal decay rate without metabolic conversion rates
R_{pyr} :	Pyruvate signal decay rate including metabolic conversion rates
lb:	Vector of lower bounds
ub:	Vector of upper bounds
m :	Index of all metabolites (lactate, alanine, pyruvate, and bicarbonate)
t_i :	Sampling times
β :	Vector of optimization parameters
$y_{m,i}$:	Measured data point for metabolite m and time step t_i
$M_m(t, \beta)$:	Time dependent signal of metabolite m as a function of parameters β .

Conflict of Interests

Marion I. Menzel, Jonathan I. Sperl, Martin A. Janich, Florian Wiesinger, and Rolf F. Schulte are employed by GE Global Research. All other authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was funded by BMBF MOBITUM Grant no. 01EZ0826/7 and BMBF Grant no. 13EZ1114. The authors take responsibility for the content of the paper. Pedro A. Gómez Damián acknowledges the support from the German Academic Exchange Service (DAAD) and the Modality of Professional Experience (MEP) from the Tecnológico de Monterrey.

References

- [1] K. M. Brindle, "NMR methods for measuring enzyme kinetics *in vivo*," *Progress in Nuclear Magnetic Resonance Spectroscopy*, vol. 20, no. 3, pp. 257–293, 1988.
- [2] J. H. Ardenkjær-Larsen, B. Fridlund, A. Gram et al., "Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 18, pp. 10158–10163, 2003.
- [3] K. Golman, R. In 't Zandt, and M. Thaning, "Real-time metabolic imaging," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 30, pp. 11270–11275, 2006.
- [4] M. E. Bizeau, C. Short, J. S. Thresher, S. R. Commerford, W. T. Willis, and M. J. Pagliassotti, "Increased pyruvate flux capacities account for diet-induced increases in gluconeogenesis *in vitro*," *American Journal of Physiology*, vol. 281, no. 2, pp. R427–R433, 2001.
- [5] M. A. Janich, M. I. Menzel, F. Wiesinger et al., "Effects of pyruvate dose on *in vivo* metabolism and quantification of hyperpolarized ^{13}C spectra," *NMR in Biomedicine*, vol. 25, no. 1, pp. 142–151, 2012.
- [6] H. J. Atherton, M. A. Schroeder, M. S. Dodd et al., "Validation of the *in vivo* assessment of pyruvate dehydrogenase activity using hyperpolarized ^{13}C MRS," *NMR in Biomedicine*, vol. 24, no. 2, pp. 201–208, 2011.
- [7] S. E. Day, M. I. Kettunen, F. A. Gallagher et al., "Detecting tumor response to treatment using hyperpolarized ^{13}C magnetic resonance imaging and spectroscopy," *Nature Medicine*, vol. 13, no. 11, pp. 1382–1387, 2007.
- [8] M. L. Zierhut, Y.-F. Yen, A. P. Chen et al., "Kinetic modeling of hyperpolarized $^{13}\text{C}_1$ -pyruvate metabolism in normal rats and TRAMP mice," *Journal of Magnetic Resonance*, vol. 202, no. 1, pp. 85–92, 2010.
- [9] D. M. Spielman, D. Mayer, Y.-F. Yen, J. Tropp, R. E. Hurd, and A. Pfefferbaum, "In vivo measurement of ethanol metabolism in the rat liver using magnetic resonance spectroscopy of hyperpolarized $[1-^{13}\text{C}]\text{pyruvate}$," *Magnetic Resonance in Medicine*, vol. 62, no. 2, pp. 307–313, 2009.
- [10] O. Khagai, R. F. Schulte, M. A. Janich et al., "Apparent rate constant mapping using hyperpolarized $[1-^{13}\text{C}]\text{pyruvate}$," *NMR in Biomedicine*, vol. 27, no. 10, pp. 1256–1265, 2014.
- [11] J. M. Park, S. Josan, T. Jang et al., "Metabolite kinetics in C6 rat glioma model using magnetic resonance spectroscopic imaging of hyperpolarized $[1-^{13}\text{C}]\text{pyruvate}$," *Magnetic Resonance in Medicine*, vol. 68, no. 6, pp. 1886–1893, 2012.
- [12] S. Josan, D. Spielman, Y.-F. Yen, R. Hurd, A. Pfefferbaum, and D. Mayer, "Fast volumetric imaging of ethanol metabolism in rat liver with hyperpolarized $[1-^{13}\text{C}]\text{pyruvate}$," *NMR in Biomedicine*, vol. 25, no. 8, pp. 993–999, 2012.
- [13] M. I. Kettunen, D.-E. Hu, T. H. Witney et al., "Magnetization transfer Measurements of exchange between hyperpolarized $[1-^{13}\text{C}]\text{pyruvate}$ and $[1-^{13}\text{C}]\text{lactate}$ in a murine lymphoma," *Magnetic Resonance in Medicine*, vol. 63, no. 4, pp. 872–880, 2010.
- [14] P. E. Z. Larson, A. B. Kerr, C. Leon Swisher, J. M. Pauly, and D. B. Vigneron, "A rapid method for direct detection of metabolic conversion and magnetization exchange with application to hyperpolarized substrates," *Journal of Magnetic Resonance*, vol. 225, pp. 71–80, 2012.
- [15] C. Harrison, C. Yang, A. Jindal et al., "Comparison of kinetic models for analysis of pyruvate-to-lactate exchange by hyperpolarized ^{13}C NMR," *NMR in Biomedicine*, vol. 25, no. 11, pp. 1286–1294, 2012.
- [16] D. K. Hill, M. R. Orton, E. Mariotti et al., "Model free approach to kinetic analysis of real-time hyperpolarized ^{13}C magnetic resonance spectroscopy data," *PLoS ONE*, vol. 8, no. 9, Article ID e71996, 2013.
- [17] L. Z. Li, S. Kadlecek, H. N. Xu et al., "Ratiometric analysis in hyperpolarized NMR (I): test of the two-site exchange model and the quantification of reaction rate constants," *NMR in Biomedicine*, vol. 26, no. 10, pp. 1308–1320, 2013.
- [18] F. A. Gallagher, M. I. Kettunen, and K. M. Brindle, "Biomedical applications of hyperpolarized ^{13}C magnetic resonance imaging," *Progress in Nuclear Magnetic Resonance Spectroscopy*, vol. 55, no. 4, pp. 285–295, 2009.
- [19] M. F. Santarelli, V. Positano, G. Giovannetti et al., "How the signal-to-noise ratio influences hyperpolarized ^{13}C dynamic MRS data fitting and parameter estimation," *NMR in Biomedicine*, vol. 25, no. 7, pp. 925–934, 2012.
- [20] M. E. Merritt, C. Harrison, C. Storey, F. M. Jeffrey, A. D. Sherry, and C. R. Malloy, "Hyperpolarized ^{13}C allows a direct measure of flux through a single enzyme-catalyzed step by NMR," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 50, pp. 19772–19777, 2007.
- [21] S. M. Kazan, S. Reynolds, A. Kennerley et al., "Kinetic modeling of hyperpolarized ^{13}C pyruvate metabolism in tumors using a measured arterial input function," *Magnetic Resonance in Medicine*, vol. 70, no. 4, pp. 943–953, 2013.
- [22] C. Yang, C. Harrison, E. S. Jin et al., "Simultaneous steady-state and dynamic ^{13}C NMR can differentiate alternative routes of pyruvate metabolism in living cancer cells," *The Journal of Biological Chemistry*, vol. 289, no. 9, pp. 6212–6224, 2014.
- [23] F. Wiesinger, I. Miederer, M. I. Menzel et al., "Metabolic rate constant mapping of hyperpolarized ^{13}C pyruvate," *ISMRM* 3282, 2010.
- [24] L. Vanhamme, A. van den Boogaart, and S. van Huffel, "Improved method for accurate and efficient quantification of mrs data with use of prior knowledge," *Journal of Magnetic Resonance*, vol. 129, no. 1, pp. 35–43, 1997.
- [25] T. Harris, G. Eliyahu, L. Frydman, and H. Degani, "Kinetics of hyperpolarized $^{13}\text{C}_1$ -pyruvate transport and metabolism in living human breast cancer cells," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 43, pp. 18131–18136, 2009.
- [26] T. Xu, D. Mayer, M. Gu et al., "Quantification of *in vivo* metabolic kinetics of hyperpolarized pyruvate in rat kidneys using dynamic ^{13}C MRSI," *NMR in Biomedicine*, vol. 24, no. 8, pp. 997–1005, 2011.
- [27] J. D. Shearer, G. P. Buzby, J. L. Mullen, E. Miller, and M. D. Caldwell, "Alteration in pyruvate metabolism in the liver of tumor-bearing rats," *Cancer Research*, vol. 44, no. 10, pp. 4443–4446, 1984.
- [28] D. M. Bates and D. G. Watts, *Nonlinear Regression Analysis and Its Applications*, John Wiley & Sons, New York, NY, USA, 2008.
- [29] O. Warburg, "On the origin of cancer cells," *Science*, vol. 123, no. 3191, pp. 309–314, 1956.
- [30] H. Lu, R. A. Forbes, and A. Verma, "Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis," *The Journal of Biological Chemistry*, vol. 277, no. 26, pp. 23111–23115, 2002.

- [31] W. Droge, H.-P. Eck, H. Kriegbaum, and S. Mihm, "Release of L-alanine by tumor cells," *The Journal of Immunology*, vol. 137, no. 4, pp. 1383–1386, 1986.
- [32] L. Brennan, C. Hewage, J. P. G. Malthouse, and G. J. McBean, "Gliotoxins disrupt alanine metabolism and glutathione production in C6 glioma cells: a ^{13}C NMR spectroscopic study," *Neurochemistry International*, vol. 45, no. 8, pp. 1155–1165, 2004.
- [33] H. R. Harding, F. Rosen, and C. A. Nichol, "Depression of Alanine Transaminase Activity in the Liver of Rats Bearing Walker Carcinoma 256," *Cancer Research*, vol. 24, pp. 1318–1323, 1964.
- [34] S. M. Ronen, A. Volk, and J. Mispelter, "Comparative NMR study of a differentiated rat hepatoma and its dedifferentiated subclone cultured as spheroids and as implanted tumors," *NMR in Biomedicine*, vol. 7, no. 6, pp. 278–286, 1994.